AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...
He had suggested that the government's top medical adviser should be "shot in the head" and railed against the creator of the ...
Irish Independent on MSN12h
Flu is leading to school absences but uptake of vaccine low – survey revealsMore than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.
These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.
Pharmaceutical giant AstraZeneca said Thursday that the head of its China operations had been detained, after reports the ...
Pharmaceutical Technology on MSN13d
EC approves AstraZeneca’s Fasenra for EGPA treatmentThe European Commission (EC) has approved AstraZeneca ‘s Fasenra (benralizumab) as an add-on therapy for adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback